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Abstract 
BACKGROUND: B-cell activating factor (BAFF) is considered to have a role in the pathogenesis of systemic 
sclerosis (SSc).  
AIM: We conducted a longitudinal study on early SSc patients to determine the change in BAFF serum level after 
treatment and its association with organ involvements.  
METHODS: A total of 46 patients (32 diffuse, 14 limited) were recruited, among which 35 patients (24 diffuse, 11 
limited) completed 12-month follow-up.  
RESULTS: Higher pretreatment BAFF levels were observed in patients with positive anti-topoisomerase antibody 
(ATA) (2252.1 ± 899.7 pg/ml versus 1475.5 ± 697.6 pg/ml in ATA-negative patients; p = 0.01) and muscular 
involvement (2741.9 ± 1039.9 pg/ml versus 1897.2 ± 762.9 pg/ml in patients without muscular involvement; p = 
0.005). Lower levels were observed in patients with interstitial lung disease (ILD) (1926.7 ± 757.9 pg/ml versus 
2721.6 ± 1131.4 pg/ml in non-ILD patients; p = 0.01). After treatment, BAFF level reduced significantly in diffuse 
SSc patients (1652.2 ± 892.7 pg/ml versus 2147.6 ± 945.5 pg/ml before treatment; p = 0.03).  
CONCLUSION: Patients with worsening outcome had the highest pretreatment BAFF level and was associated 
with increased BAFF level after treatment. BAFF can be used to predict and monitor patients’ response to 
therapy. 
 
 
 
 
 
 
 
 
Introduction 
 
BAFF (B lymphocyte stimulator, BlyS) plays 
the most important role in the survival and maturation 
of B lymphocytes (B cells) [1]. Recent studies have 
shown that B cells may play an important role in 
mediating immune responses in systemic sclerosis 
(SSc). In SSc patients, although the amount of B cells 
does not increase in skin lesions, activating markers 
are found to increase. Functional abnormalities of B 
cells can cause systemic diseases independent with 
antibody-producing function [2]. The BAFF/BAFFR 
family are present in almost all the stages of B cell 
differentiation and maintain the survival of B cells in 
bone marrow. BAFF also has strong in vitro B cell 
stimulating function [3]. Therefore, excessive BAFF 
increase causes self-activation of B cells, playing an 
important role in the development of autoimmune 
diseases. Previous studies on SSc Japanese patients 
with systemic lupus erythematosus (SLE), rheumatoid 
arthritis, and Sjogren’s syndrome have demonstrated 
high serum levels of BAFF. Belimumab (a soluble 
monoclonal anti-BAFF antibody) has been approved 
by the Food and Drug Administration (FDA) for the 
treatment of SLE patients [4]. Other studies have also 
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shown that in SSc patients, increased BAFF levels are 
associated with sclerotic skin lesions, lung’s vital 
capacity, and musculoskeletal involvements. This 
suggests that BAFF is a signal of abnormal B cell 
activation and the development of SSc [5]. A multi-
centre clinical randomised controlled trial on rituximab, 
a monoclonal anti-CD20 antibody that inhibits B cells, 
has shown improvement on ILD and decreased 
mRSS [6]. Therefore, BAFF is one of the targets that 
should be considered in the treatment of SSc.  
To evaluate B cells’ activity in early SSc 
patients, we conducted a study with two aims: 
1. To determine the change in serum BAFF 
level in SSC patients before and after treatment at the 
National Hospital of Dermatology and Venerology; 
2. To explore the association of changes in 
BAFF level with skin and organ involvement in SSC 
patients. 
 
 
Methods 
 
We recruited 46 patients diagnosed with SSc 
based on the 2013 EULAR/ACR classification criteria 
[7] who were treated at the National Hospital of 
Dermatology and Venereology (NHDV) from 
December 2014 to December 2017. Selection criteria 
included patients who had an onset of ≤ 36 months, 
were naïve to treatment or had stopped 
immunosuppressive and antifibrotic therapy for ≥ 2 
months, had no concomitant skin diseases such as 
skin infection or overlap syndrome. The patients were 
treated with methylprednisolone, methotrexate, 
vasodilators, and other symptomatic treatments 
according to the European guidelines on SSc 
management [8] and were followed up in at least 12 
months. 
Data collection included demographics (sex, 
age, onset, disease duration) and clinical and 
laboratory parameters at baseline and 12-month 
follow-up. Patients were assessed for skin lesions 
(using the modified Rodnan Skin Score-mRSS), digital 
tip ulcer, telangiectasia, interstitial lung disease (ILD, 
using high-resolution computed tomography-HRCT), 
pulmonary arterial hypertension (PAH, using the cutoff 
≥ 35 mmHg of the systolic pulmonary artery pressure-
PAPs on transthoracic echocardiography-TTE), 
urinalysis abnormality (observed on ≥ 2 tests), 
difficulty swallowing, joint pain, and muscle injury (at 
least 2 out of 3 findings: muscle pain/weakness, 
creatinine kinase-CK level higher than normal limit at 
the time of presentation, and needle 
electromyography-EMG demonstrating muscle 
diseases). Severity was classified as mild, moderate, 
and severe if patients had zero, one, and two or more 
organ involvements, respectively. Improvement and 
worsening were determined by changes in 
constitutional symptoms and at least two systems 
(healing or new lessons of digital tip ulcer, improved 
or worsened difficulty swallowing, joint pain, or 
muscular involvement, a difference of ≥ 2 points in the 
ILD score, and a difference of ≥ 5 mmHg in PAPs 
between recruitment and follow-up). 
Serum specimens were obtained and stored 
at baseline and 12 months after treatment, following 
the standard operating procedures at the NHDV-3 mL 
of venous blood was drawn into a collecting tube 
without anticoagulant, left in the room temperature in 
30 minutes, and centrifuged at 2000 rpm in 15 
minutes. The serum was then extracted to a 1.5 mL 
Eppendorf tube and stored in a minus 80°C freezer. 
Some autoimmune antibodies were tested in 
Vietnam. Antinuclear antibody (ANA) and anti-
centromere antibody (ACA) were tested using indirect 
immunofluorescence on Hep-2 cells (Fluoro Hepana, 
MBL, Japan). Anti-topoisomerase antibody (ATA) was 
tested by enzyme-linked immunosorbent assay 
(ELISA; Medical & Biological Laboratories, Nakaku, 
Nagoya, Japan). 
Anti-RNA polymerase antibody (RNAP) was 
tested by ELISA in Japan (Mesacup anti-RNA, 
Japan). The level of BAFF was measured by ELISA, 
using Quantikines ELISA Human BAFF/BLyS/ 
TNFSF13B Immunoassay (R&D Systems China 
Company). 
Data analysis was performed using SPSS 
20.0 (IBM Corporation). Continuous variables were 
tested for the difference by the independent t-test (for 
normally distributed variables) or the Mann-Whitney U 
test or the Kruskal-Wallis test (for not normally 
distributed variables). Paired continuous variables 
were tested for the difference by the paired t-test (for 
normally distributed variables) or the Wilcoxon Signed 
Ranks test (for not normally distributed variables). 
Categorical variables were tested for the difference by 
the chi-squared test. 
The study has been approved by the Hanoi 
Medical University and the NHDV. 
 
 
Results 
 
A total of 46 patients were recruited in our 
study, among which 32 (65.9%) patients had diffuse 
SSc and 14 (30.4%) limited SSc. The mean age of 
onset was 50.1 ± 14.1 years, and the mean duration 
from the onset was 11.5 ± 8.4 months; no difference 
was observed between diffuse and limited SSc 
patients. Before treatment, 36 out of 45 patients had 
positive ATA. The mean level of ATA in diffuse SSc 
patients was higher than in limited SSc patients (p = 
0.008). Only two patients had positive ACA and one 
positive RNAP. The mean pretreatment mRSS was 
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15.0 ± 8.9 (18.7 ± 7.9 and 6.6 ± 3.8 in diffuse SSc and 
limited SSc patients, respectively; p < 0.001). The 
proportions of other involvements were presented in 
Table 1. 
Table 1: Patient baseline characteristics 
 Total 
(n = 46) 
Diffuse SSc 
(n = 32) 
Limited SSc 
(n = 14) 
p
*
 
Female:male (n) 32:14 2:1 11:3 NS 
Age of onset (year; mean ± SD) 50.1 ± 14.1 49.0 ± 14.7 52.5 ± 12.9 NS 
Duration from onset (month; mean 
± SD) 
11.5 ± 8.4 11.5 ± 7.7 11.4 ± 9.9 NS 
ATA (mmol/ml; mean ± SD) 123.1 ± 82.6 143.3 ± 75.7 73.3 ± 80.4 0.008 
ATA (n; %) 36; 80% 28; 87.5% 8; 61.5% NS 
ACA (n; %) 2; 4.3%    
RNAP (n; %) 1; 2.2%    
mRSS (mean ± SD) 15.0 ± 8.9 18.7 ± 7.9 6.6 ± 3.8 0.0001 
Digital tip ulcer (n; %) 10; 21.7% 7; 21.9% 3; 21.4% NS 
Telangiectasia (n; %) 14; 30.4% 10; 31.2% 4; 28.6% NS 
ILD (n; %) 36; 78.3% 25; 78.1% 11; 78.6% NS 
PAH (n; %) 16; 34.8% 9; 28.1% 7; 50.0% NS 
Urinalysis abnormality (n; %) 10; 21.7% 6; 18.8% 4; 28.6% NS 
Difficulty swallowing (n; %) 9; 19.6% 7; 21.9% 2; 14.3% NS 
Joint pain (n; %) 25; 54.3% 19; 59.4% 6; 42.9% NS 
Muscular involvement (n; %) 11; 23.9% 8; 25.0% 3; 21.4% NS 
*: t-test for continuous variables; chi-squared test for categorical variables. NS: not 
significant; SD: standard deviation. 
 
Pretreatment BAFF level 
There was no difference in the pretreatment 
BAFF level in diffuse and limited SSc patients (2010.4 
± 907.6 pg/ml versus 2177.2 ± 1009.3 pg/ml; p = 
0.58). BAFF level was higher in patients with positive 
ATA, and this difference was more prominent in 
diffuse SSc patients. BAFF level was lower in patients 
with ILD, but the difference was not statistically 
significant in limited SSc patients. BAFF level was 
higher in patients with muscular involvement, and this 
difference was more prominent in limited SSc 
patients. The number (proportion) of patients with 
mild, moderate, and severe SSc was 10 (21.7%), 13 
(28.3%), and 23 (50%), respectively as shown in 
Table 2. 
Table 2: BAFF level by SSc types and clinical and laboratory 
findings 
BAFF 
(pg/ml) 
SSc Diffuse SSc Limited SSc 
Concentration P
*
 Concentration P
*
 Concentration p
**
 
ATA 
Present 
Absent 
 
2252.1 ± 899.7 
1475.5 ± 697.6 
0.02  
2202.2 ± 822.7 
1104.5 ± 491.7 
0.01  
2426.7 ± 1180.0 
1772.3 ± 737.6 
NS 
Digital tip ulcer 
Present 
Absent 
 
2440.3 ± 1033.0 
2004.4 ± 853.4 
NS  
2191.2 ± 736.4 
2029.7 ± 908.7 
NS  
3021.6 ± 1565.7 
1946.9 ± 749.5 
NS 
Telangiectasia 
Present 
Absent 
 
2142.1 ± 762.8 
2080.4 ± 966.8 
NS  
2117.6 ± 822.7 
2041.1 ± 901.9 
NS  
2203.4 ± 695.7 
2166.8 ± 1144.4 
NS 
ILD 
Present 
Absent 
 
1926.7 ± 757.9 
2721.6 ± 1131.4 
0.01  
1895.2 ± 783.2 
2671.4 ± 930.9 
0.03  
1996.9 ± 728.6 
2838.7 ± 1769.6 
NS 
PAH 
Present 
Absent 
 
2220.2 ± 849.1 
2034.6 ± 936.0 
NS  
2431.0 ± 860,6 
1921.8 ± 842.4 
NS  
1949.1 ± 813.9 
2405.4 ± 1192.9 
NS 
Urinalysis 
abnormality 
Present 
Absent 
 
 
1806.2 ± 661.2 
2180.6 ± 949.4 
NS  
 
1855.8 ± 857.6 
2113.3 ± 876.7 
NS  
 
1731.8 ± 271.2 
2355.4 ± 1150.4 
NS 
Difficulty 
swallowing 
Present 
Absent 
 
 
1982.9 ± 1062.1 
2127.4 ± 872.5 
NS  
 
1838.9 ± 1170.0 
2128.3 ± 778.5 
NS  
 
2486.9 ± 396.8 
2125.6 ± 1081.3 
NS 
Joint pain 
Present 
Absent 
 
2158.0 ± 901.7 
2029.1 ± 918.6 
NS  
2225.5 ± 953.8 
1830.4 ± 685.2 
NS  
1944.3 ± 745.0 
2351.9 ± 1189.1 
NS 
Muscular 
involvement 
Present 
Absent 
 
 
2741.9 ± 1039.9 
1897.2 ± 762.9 
0.005  
 
2570.3 ± 924.8 
1896.6 ± 794.1 
NS  
 
3199.6 ± 1407.9 
1898.4 ± 727.1 
0.04 
Severity [median 
(min-max)]
***
 
Mild 
Moderate 
Severe 
 
 
1532.0 (649-3012) 
1897.1 (430-3564) 
2279.1 (1201-4820) 
NS  
 
1536.7 (1178-
3012) 
1764.7 (430-3564) 
2279.5 (1201-
3735) 
NS  
 
1532.0 (650-2499) 
2665.1 92563-
2767) 
2242.7 (1204-
4820) 
NS 
*: t-test; **: Mann-Whitney U test; ***: Kruskal-Wallis test. NS: not significant. 
 
Changes of BAFF level after treatment 
In 35 (76.1%) patients (24 diffuse SSc, 11 
limited SSc) who completed 12-month follow-up, the 
mean BAFF level significantly reduced compared to 
before treatment (1652.2 ± 892.7 pg/ml versus 2147.6 
± 945.5 pg/ml; p = 0.03). However, when stratified by 
types of SSc, only diffuse SSc patients demonstrated 
significant reduction in BAFF level (1440.8 ± 637.0 
pg/ml versus 2094.7 ± 875.9 pg/ml; p = 0.002) while 
this reduction in limited SSc patients was not 
significant [median (min-max) 1641.5 (1333.2-5523.2) 
versus 2279.1 (648.9-4820.4) pg/ml; p = 0.52] as 
presented in Figure 1a. 
 
Figure 1: BAFF level before and after treatment; a) BAFF level 
before and after treatment in all patients and stratified by types of 
SSc; b) BAFF level before and after treatment among patients with 
clinically improved, not changed, and worsened outcome. 
Comparisons between before and after treatment were made by the 
paired t-test (for all patients and diffuse SSc patients) and the 
Wilcoxon signed rank test (for limited SSc patients). Comparisons 
among outcome groups were made by the Kruskal-Wallis test. NS: 
not significant; *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 
0.0001 
 
When stratified by outcomes at follow-up (18 
improved, 9 not changed, and 8 worsened), there 
were differences in the BAFF level among outcome 
groups both at baseline and follow-up, and the 
differences in the reduction of BAFF level after 12 
months were significantly different as presented in 
Figure 1b. In particular, patients with clinical 
improvement had the highest baseline BAFF level 
(median 2531.1, min-max 1257.5-4820.4) and was 
associated with the greatest reduction in BAFF level 
(median difference 1137.5, min-max 572.0-2405.5) 
while patients with clinical worsening had the lowest 
baseline BAFF level (median 1333.8, min-max 429.5-
1764.7) and was associated with an increase in BAFF 
level (median difference 1993.15, min-max 1123.4-
5523.2). 
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Discussions 
 
In our study, higher BAFF levels were 
observed in patients with positive anti-topoisomerase 
antibody (ATA), ILD, and muscular involvement. ATA 
is more prevalent in diffuse SSc patients, and its 
presence has been associated with lung involvement 
[9]. BAFF’s relationship with ATA in SSc has not been 
established, but a previous study has shown no 
correlation between ATA and BAFF in systemic lupus 
erythematosus (SLE) and rheumatoid arthritis [10]. 
Although decreased lung vital capacity has 
been observed in patients with elevated BAFF, 
pulmonary fibrosis, the hallmark of ILD, seems to be 
associated with high APRIL (a proliferation-inducing 
ligand) levels but not high BAFF levels [11]. While 
BAFF is related to the survival and proliferation of B 
cells, increased levels of BAFF were not shown to 
correlate with the number of B cells in peripheral 
blood—in fact, studies have shown that the number of 
B cells was decreased in SSc [12], [13]. Findings from 
studies on experimental animals suggested 
interleukin-6 (IL-6) and IL-10 play a more prominent 
role in the development and attenuation of lung 
fibrosis, and BAFF might suppress regulatory B cells 
(which produces IL-10 and decreases immune 
response) [14]. Based on a study in 15 years, 
Yoshizaki and Sato have proposed a model of 
abnormal B cells’ activity [15]. In this model, 
augmentation of B-cell antigen receptor (BCR) 
signalling, along with overproduction of BAFF and 
TLR stimulation, induces activation of memory B cells 
and increases apoptosis. This, in turn, decreases the 
number of peripheral B cells. To maintain the number 
of inactivated B cells, bone marrow will increase the 
production of naïve B cells into peripheral blood. 
Therefore, there is an increase in the number of naïve 
B cells but a decrease in the number of memory B 
cells in early SSc patients [16]. B cells are mainly 
active in peripheral blood but not in organ tissues, and 
the number of peripheral B cells increases after 
treatment [17] in this study and another study [18]. 
BAFF antagonist or genetic ablation of BAFF 
attenuated lung fibrosis. However, these findings are 
limited to animal experiments and might not reflect the 
whole picture of a more complex cytokine network in 
human. 
Studies on cytokines in muscular diseases 
started in 1986 with the identification of IL-2 and 
interferon (IFN) in polymyositis. Since then, 
researchers have described multiple cytokines relating 
to a spectrum of muscular diseases. However, there 
was no association of muscular involvement with 
levels of cytokines in SSc [19]. Our study is the first 
study to show a higher level of BAFF in patients who 
had muscular involvement. 
Although both diffuse and limited SSc patients 
in our study demonstrated a reduction in the level of 
BAFF after 12 months of treatment, only diffuse 
disease patients had a significant reduction. 
Matsushita et al. found that the reduction of BAFF 
levels in SSc was more modest than in SLE but still 
more significant than in dermatomyositis [5]. Patients 
in both Matsushita’s and our study had an onset within 
2–3 years, suggesting BAFF can be elevated at a very 
early stage of SSc. 
The most surprising finding in our study was 
that higher pretreatment BAFF levels were observed 
in patients with clinical improvement but not in 
patients with clinical worsening. Patients with 
improvement also had more significant reduction of 
BAFF levels after treatment. In a previous study, 
increased levels of BAFF have been considered to 
herald the development or worsening of major events 
in SSc whereas decreased levels of BAFF was 
associated with regression of skin involvement [5]. 
The evidence suggests the level of BAFF before 
treatment could be used for prognosis and changes in 
BAFF level can help monitor patients’ treatment 
progress. 
In conclusion, the level of BAFF was 
significantly higher in early SSc patients and related to 
ATA production of B lymphocytes. Pretreatment BAFF 
level was lower in the presence of ILD on HRCT and 
higher in the presence of muscular involvement. 
Clinical worsening after 12 months of treatment was 
associated with higher pretreatment BAFF level and 
increase in follow-up BAFF level compared to 
baseline. This suggests that baseline BAFF level as 
well as it changes after treatment can be used to 
predict and monitor patients’ response to therapy. 
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